Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus
Tools
Tools
Tools
Annels, Nicola, Arif, Mehreen, Simpson, Guy, Denyer, Mick, Moller-Levet, Carla, Mansfield, David, Butler, Rachel, Shafren, Darren, Au, Gough, Knowles, Margaret , Harrington, Kevin, Vile, Richard, Melcher, Alan and Pandha, Hardev (2018) Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus Molecular Therapy - Oncolytics, 9. pp. 1-12.
|
Text
mmc2.pdf - Version of Record Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (3MB) | Preview |
Official URL: https://doi.org/10.1016/j.omto.2018.02.001
Abstract
As a clinical setting in which local live biological therapy is already well established, non-muscle invasive bladder cancer (NMIBC) presents intriguing opportunities for oncolytic virotherapy. Coxsackievirus A21 (CVA21) is a novel intercellular adhesion molecule-1 (ICAM-1)-targeted immunotherapeutic virus. This study investigated CVA21-induced cytotoxicity in a panel of human bladder cancer cell lines, revealing a range of sensitivities largely correlating with expression of the viral receptor ICAM-1. CVA21 in combination with low doses of mitomycin-C enhanced CVA21 viral replication and oncolysis by increasing surface expression levels of ICAM-1. This was further confirmed using 300-μm precision slices of NMIBC where levels of virus protein expression and induction of apoptosis were enhanced with prior exposure to mitomycin-C. Given the importance of the immunogenicity of dying cancer cells for triggering tumor-specific responses and long-term therapeutic success, the ability of CVA21 to induce immunogenic cell death was investigated. CVA21 induced immunogenic apoptosis in bladder cancer cell lines, as evidenced by expression of the immunogenic cell death (ICD) determinant calreticulin, and HMGB-1 release and the ability to reject MB49 tumors in syngeneic mice after vaccination with MB49 cells undergoing CVA21 induced ICD. Such CVA21 immunotherapy could offer a potentially less toxic, more effective option for the treatment of bladder cancer.
| Item Type: | Article | |||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Divisions : | Faculty of Health and Medical Sciences > School of Biosciences and Medicine | |||||||||||||||||||||||||||||||||||||||||||||
| Authors : |
|
|||||||||||||||||||||||||||||||||||||||||||||
| Date : | 14 February 2018 | |||||||||||||||||||||||||||||||||||||||||||||
| DOI : | 10.1016/j.omto.2018.02.001 | |||||||||||||||||||||||||||||||||||||||||||||
| Copyright Disclaimer : | © 2018 The Authors. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/) | |||||||||||||||||||||||||||||||||||||||||||||
| Depositing User : | Melanie Hughes | |||||||||||||||||||||||||||||||||||||||||||||
| Date Deposited : | 13 Nov 2018 10:34 | |||||||||||||||||||||||||||||||||||||||||||||
| Last Modified : | 13 Nov 2018 10:34 | |||||||||||||||||||||||||||||||||||||||||||||
| URI: | http://epubs.surrey.ac.uk/id/eprint/849859 |
Actions (login required)
 |
View Item |
Downloads
Downloads per month over past year